Neuropsychological Test Performance in Healthy Volunteers Before and After Donepezil Administration

Abstract

Participants in early Phase I clinical trials for drugs designed to enhance cognition are typically healthy volunteers. If improvement can be detected with a battery of cognitive tests in healthy volunteers, such a battery could be a pharmacodynamic marker in the future development of the compound for treatment of cognitive disorders. In the present exploratory study, a battery of neuropsychological (NP) tests was used to determine if changes in cognition from a pharmacological intervention could be detected in healthy volunteers. A drug with known cognitive-enhancing effects in Alzheimer’s disease, donepezil, was compared with placebo and no treatment arms. Carry-over effects of repeated test administration were also assessed. In this double-blind study, 27 healthy adults were randomized into one of three arms (eight donepezil, nine placebo and 10 no treatment) and completed 14 days of donepezil (5 mg q.h.s.) or placebo (q.h.s.). A battery of NP tests was administered on days 0, 7, 14 (randomization), 21, 28 (end of treatment) and 42 (washout). There were no differences in performance between the placebo and the no treatment arms. However, on day 21, subjects in the donepezil group performed slightly but significantly worse on some tests of speed, attention and memory (p < 0.05) compared to the pooled control group (placebo and no treatment arms). No improvement in performance was present while on donepezil at days 21 or 28. While the results are counter to expectations, some tests in the battery did detect a cognitive change (transient mild worsening during drug administration) in healthy volunteers.

References

Davis K L, Hollister L E, Overall J, Johnson A, Train K (1976) Physostigmine: effects on cognition and affect in normal subjects . Psychopharmacology 21: 23–27

Davis K L, Mohs R C, Tinklenberg J R, Pfefferbaum A, Hollister L E, Kopell B S (1978) Physostigmine: enhancement of long-term memory processes in normal humans . Science 201: 272–274

Drachman DA, Leavitt J (1974) Human memory and the cholinergic system . Arch Neurol 30: 113–121

Evans D A, Funkenstein H H, Albert M S, Scherr P A, Cook N R, Chown M J, Herbert L E, Hennekens C H, Taylor J O (1989) Prevalence of Alzheimer’s disease in a community population of older persons. higher than previously reported . JAMA 262: 2551–2556

Fastenau P S, Hankins W TMcGinnis C M (2001) Content validity of five alternate forms for six established neuropsychological tests [abstract] . Arch Clin Neuropsychol 16: 824

Fastenau P S, Hankins W T, McGinnis C M, Moy T, Richard M (2002) Effects of alternate forms on retest effects in clinical testing [abstract] . J Int Neuropsychol Soc 7: 151

Folstein M F, Folstein S EMcHugh P R (1975) Mini-mental state: a practical method for grading the cognitive state of patients for clinicians . J Psychiatr Res 12: 189–195

Furey M L, Pietrini P, Haxby J (2000) Cholinergic enhancement and increased selectivity of perceptual processes during working memory . Science 290: 2315–2319

Gilmore M L, Erickson J D, Varoqui H, Hersh L B, Bennett D A, Cochran E J, Mufson E J, Levey A I (1999) Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer’s disease . J Compar Neurol 411: 693–704

10.

Graham J E, Rockwood K, Beattie E L, Eastwood R, Gauthier S, Tuokko H, McDowell I (1997) Prevalence and severity of cognitive impairment with and without dementia in an elderly population . Lancet 349: 1793–1796

11.

Horton A (1999) Above-average intelligence and neuropsychological test score performance . Int J Neurosci 99: 221–231

12.

Kareken D A, Gur R C, Saykin A J (1995) Reading on the Wide Range Achievement Test–Revised and parental education as predictors of IQ: comparison with the Barona formula . Arch Lin Neuropsychol 10: 147–157

13.

Lezak M (1995) Neuropsychological assessment, 3rd edn. Oxford University Press, New York

14.

Rogers S L, Friedhoff L T (1996) The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicenter, randomized, double-blind, placebo-controlled trial . Dementia 7: 293–303

15.

Rogers S L, Farlow M R, Doody R S, Mohs R, Friedhoff L T (1998) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease . Neurology 50: 136–145

16.

Rosen W G, Mohs R C, Davis K L (1984) A new rating scale for Alzheimer’s disease . Am J Psychiatry 141: 1356–1364

17.

Schmidt M (1996) Rey auditory verbal learning test: a handbook. Western Psychological Services, Los Angeles

18.

Schneider L S (2001) Treatment of Alzheimer’s disease with cholinesterase inhibitors . Clin Geriatr Med 17: 337–358

19.

Sitaram N, Weingartner H (1978) Human serial learning: enhancement with arecholine and choline and impairment with scopolamine . Science 201: 274–276

20.

Wechsler D (1991) Wechsler adult intelligence scale–III. Psychological Corporation, New York

21.

Wilkinson G S (1993) Wide range achievement test, 3rd edn. Wide Range, Inc., Delaware

22.

Yesavage J A, Mumenthaler M S, Taylor J L, Friedman L, O’Hara R, Sheikh J, Tinklenberg J, Whitehouse P J (2002) Donepezil and flight simulator performance: effects on retention of complex skills . Neurology 59: 123–125